Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aaron R Hansen

Showing results (71-80 of 172) with videos related to

Pageof 18
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2022
A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell CarcinomaMartin H Voss, Arun A Azad, Aaron R Hansen, et al.
Cancer Medicine|October 11, 2023
Selinexor for the treatment of recurrent or metastatic salivary gland tumors: Results from the GEMS-001 clinical trialAlberto Hernando-Calvo, Eoghan Malone, Daphne Day, et al.
The Canadian Journal of Urology|August 11, 2021
The financial impact of cancer care on renal cancer patientsDoreen A Ezeife, Brendon Josh Morganstein, Steven Yip, et al.
European Journal of Cancer (Oxford, England : 1990)|July 1, 2022
Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 studyCaroline Even, Jean-Pierre Delord, Katharine A Price, et al.
Current Oncology (Toronto, Ont.)|February 24, 2021
The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular CancerDomen Ribnikar, Igor Stukalin, Philippe L Bedard, et al.
European Urology|August 17, 2016
Conditional Risk of Relapse in Surveillance for Clinical Stage I Testicular CancerMadhur Nayan, Michael A S Jewett, Ali Hosni, et al.
The Oncologist|January 20, 2025
A first-in-human study of JNJ-70218902, a bispecific T-cell-redirecting antibody against TMEFF2 in metastatic castration-resistant prostate cancerEmiliano Calvo, Bernard Doger, Joan Carles, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2017
Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 StudyChiun Hsu, Se-Hoon Lee, Samuel Ejadi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2022
Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 StudyDavid M O'Malley, Giovanni Mendonca Bariani, Philippe A Cassier, et al.
British Journal of Cancer|May 21, 2019
A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trialGrainne M O'Kane, Shereen Ezzat, Anthony M Joshua, et al.
Pageof 18

Showing results (71-80 of 172) with videos related to

Sort By:
Pageof 18
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2022
A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell CarcinomaMartin H Voss, Arun A Azad, Aaron R Hansen, et al.
Cancer Medicine|October 11, 2023
Selinexor for the treatment of recurrent or metastatic salivary gland tumors: Results from the GEMS-001 clinical trialAlberto Hernando-Calvo, Eoghan Malone, Daphne Day, et al.
The Canadian Journal of Urology|August 11, 2021
The financial impact of cancer care on renal cancer patientsDoreen A Ezeife, Brendon Josh Morganstein, Steven Yip, et al.
European Journal of Cancer (Oxford, England : 1990)|July 1, 2022
Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 studyCaroline Even, Jean-Pierre Delord, Katharine A Price, et al.
Current Oncology (Toronto, Ont.)|February 24, 2021
The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular CancerDomen Ribnikar, Igor Stukalin, Philippe L Bedard, et al.
European Urology|August 17, 2016
Conditional Risk of Relapse in Surveillance for Clinical Stage I Testicular CancerMadhur Nayan, Michael A S Jewett, Ali Hosni, et al.
The Oncologist|January 20, 2025
A first-in-human study of JNJ-70218902, a bispecific T-cell-redirecting antibody against TMEFF2 in metastatic castration-resistant prostate cancerEmiliano Calvo, Bernard Doger, Joan Carles, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2017
Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 StudyChiun Hsu, Se-Hoon Lee, Samuel Ejadi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2022
Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 StudyDavid M O'Malley, Giovanni Mendonca Bariani, Philippe A Cassier, et al.
British Journal of Cancer|May 21, 2019
A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trialGrainne M O'Kane, Shereen Ezzat, Anthony M Joshua, et al.
Pageof 18